Erasca, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonathan E. Lim
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10835 Road to the Cure San Diego CA United States of America 92121
- IPO Date
- Jul 16, 2021
- CIK
- 0001761918
- Website
- erasca.com
- Similar Companies
- Business
- Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers, which affect approximately 30% of human cancers; its pipeline includes naporafenib, a pan-RAF inhibitor for NRAS-mutant melanoma and RAS Q61X solid tumors studied in over 600 patients; ERAS-007, an oral ERK1/2 inhibitor for colorectal cancer, non-small cell lung cancer, and advanced gastrointestinal malignancies; ERAS-601, an oral SHP2 inhibitor for advanced solid tumors; ERAS-0015, a pan-RAS molecular glue evaluated in Phase 1 AURAS-1 trial for RAS-mutant solid tumors following FDA IND clearance in May 2025 and recent U.S. composition-of-matter patent issuance; ERAS-4001, a pan-KRAS inhibitor with FDA IND clearance for (K)RAS-mutant solid tumors; and ERAS-801, a CNS-penetrant EGFR inhibitor for recurrent glioblastoma multiforme, alongside a bispecific antibody targeting wildtype EGFR overexpression in head and neck squamous cell carcinoma and colorectal cancer. The company pursues three strategies: targeting upstream/downstream RAS/MAPK nodes, RAS directly, and resistance escape routes, with programs in Phase 1/2 trials including HERKULES-3 for ERAS-007 combinations, SEACRAFT-2 for naporafenib with Novartis' trametinib, and ongoing evaluations of monotherapy and combinations across multiple tumor types. Founded in 2018 and headquartered in San Diego, California, Erasca operates globally in clinical development, leveraging partnerships such as licensing agreements with Guangzhou Joyo Biotech for pan-RAS inhibitors, Medshine for pan-KRAS inhibitors, NiKang Therapeutics, Asana BioSciences, and Katmai Pharmaceuticals; recent developments encompass FDA IND approvals for ERAS-0015 and ERAS-4001 in 2025, preclinical data presentations at the AACR Annual Meeting in April 2025 highlighting superior potency, Q3 2025 business updates advancing the RAS franchise toward 2026 Phase 1 data readouts, and a cash position funding operations into late 2028.
ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
INVESTOR ALERT: Erasca, Inc. (NASDAQ: ERAS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
DEADLINE ALERT for ERAS, NNOX, MSFT, BRCB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline